BioCryst Pharmaceuticals | BCRX - 流动负债

股票价格

9.78

每天变化

0.08 0.82%

每月一次

28.52%

每年

21.49%

Q1 预测

9.41

金融业

USD

USD 514.16M

现金及等价物

USD 335.91M

USD 9.52M

USD 404.35M

USD 196.07M

USD 828.6M

股息收益率

0

USD 260.39M

USD 51.7M

536

EPS每股收益

USD 1.17

股本和储备

USD -119.15M

USD 153.05M

债务利息支出

USD 14.14M

USD -0.13

USD 428.67M

USD 2.05B

USD 245.85M

USD 146.17M

USD 260.39M

普通股股本

USD 213.06M

6.06

USD 248.02M

USD 406.56M

销售和管理费用

USD 95.78M

USD 5.4M

贸易债权人

USD 15.83M

应收帐款人

USD 106.82M

	流动负债	更改		日
Alnylam Pharmaceuticals	USD 1.47B		89.13M	2025-12
BioCryst Pharmaceuticals	USD 196.07M		5.83M	2025-12
Chugai Pharma	JPY 411.08B		143.65B	2025-12
Daiichi Sankyo	JPY 778.55B		77.51B	2025-12
DBV Technologies	USD 49.48M		60K	2025-09
Enanta Pharmaceuticals	USD 44.73M		3.83M	2025-12
Gilead Sciences	USD 11.81B		485M	2025-12
GlaxoSmithKline	GBP 21.39B		57M	2025-12
Glaxosmithkline	GBP 28.82B		144.79M	2025-12
Incyte	USD 1.52B		176.44M	2025-12
Ionis Pharmaceuticals	USD 783M		120.46M	2025-12
Karyopharm Therapeutics	USD 87.16M		12.06M	2025-09
Neurocrine Biosciences	USD 743.4M		105.4M	2025-12
Novavax	USD 459.95M		30.08M	2025-12
PTC Therapeutics	USD 968.43M		102.18M	2025-12
Regeneron Pharmaceuticals	USD 4.37B		56.7M	2025-12
Roche Holding	CHF 28B		421M	2025-12
Sarepta Therapeutics	USD 1.1B		173.86M	2025-12
Ultragenyx Pharmaceutical	USD 340.02M		46.78M	2025-09
Vertex Pharmaceuticals	USD 3.86B		614.1M	2025-12